6 September 2022 - Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival. ...
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...
18 August 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
3 August 2022 - NICE has published evidence-based recommendations on the use of pralsetinib (Gavreto) for the treatment of adults ...
27 July 2022 - NICE has published a final technology appraisal for duvelisib for the treatment of patients with relapsed ...
14 July 2022 - The first new mesothelioma treatment to be approved in nearly 15 years will be made available ...
14 July 2022 - Thousands of people a year with advanced breast cancer will benefit from a life extending drug ...
14 July 2022 - An agreement with the companies on the price of two breast cancer treatments, Piqray and Trodelvy, has ...
8 July 2021 - The therapy will be used for specific muscle invasive urothelial cancer patients ...
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...
15 June 2022 - It should not come as a surprise that it is for a cancer medicine. ...
25 May 2022 - NICE has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab) as the first and only ...
25 May 2022 - An estimated 100 people per year with triple negative breast cancer that has spread to other ...
23 May 2022 - Ibrutinib, a drug used to treat Waldenström’s macroglobulinaemia, is not being recommended by NICE in England ...